人参皂甙Rg3联合小剂量化疗抑制小鼠S-180肉瘤血管生成的作用

目的：观察人参皂甙Rg3联合持续小剂量环磷酰胺（CTX）对小鼠S-180肉瘤肿瘤血管生成的影响、抑瘤作用及毒副反应。方法：建立S-180肉瘤小鼠移植性肿瘤模型，60只小鼠随机分为4组，分别为人参皂甙Rg3组（5mg／kg）、CTX组（5mg／kg）、联合治疗组（人参皂甙Rg3和CTX的联合治疗）及模型对照组。治疗结束后测定肿瘤组织重量、肿瘤微血管密度（MVD）和血管内皮生长因子（vEGF）表达情况。结果：人参皂甙Rg3组、CTX组和联合治疗组小鼠移植瘤的瘤重较对照组降低（P〈0．05），肿瘤抑制率分别为36．12％、49．43％、71．10％，MVD及VEGF的表达较对照组均下降（P〈0．05），其中联合治疗组更明显（P〈0．05）。联合治疗组小鼠毒副作用较轻，生存质量较好。结论：小剂量CTX与人参皂甙Rg3联合应用显示出明显的抗血管生成协同作用，抑瘤效果显著，且毒副反应小。     

天花粉蛋白对荷人肝癌裸小鼠的抑癌作用

目的 探讨天花粉蛋白(trichosanthin,TCS)对荷人肝癌裸小鼠的抑癌作用。方法 采用人肝癌原位移植模型。将24只裸小鼠分为TCSⅠ组、TCSⅡ组、TCSⅢ组和对照组，TCS剂量分别为0．2mg／kg、0．4mg／kg、0．6mg／kg，对照组用生理盐水0．2ml／只腹腔注射，共10次。第21天称瘤重和裸小鼠体重，计算抑癌率。应用免疫组织化学技术，检测瘤组织中Ki67的表达。结果 对照组、TCSⅠ组、TCSⅡ组和TCSⅢ组平均瘤重分别为0．99g、0．81g、0．22g和0．20g。用药组瘤重与对照组相比有显著性差异(P＜0．05)。TCSⅠ组、TCSⅡ组和TCSⅢ组抑癌率分别为18．18％、77．78％、79．80％。对照组、TCSⅠ组、TCSⅡ组和TCSⅢ组平均鼠重增加为2．22g、1．22g、0．28g、一2．37g。用药组与对照组鼠重变化有显著性差异(P＜0．05)。对照组、TCSⅠ组、TCSⅡ组和TCSⅢ组Ki67蛋白阳性表达百分率分别为31．33％、29．92％、10．25％和9．67％。TCSⅠ组Ki67百分率与对照组相比无显著性差异(P＞0．05)。TCSⅡ组和TCSⅢ组Ki67百分率与对照组相比有显著性差异(P＜0．05)。结论 TCS对荷人肝癌裸小鼠的移植瘤有明显的抑癌作用。TCS抑制肿瘤细胞增殖可能是其抑癌的机制之一。     

植入式丝裂霉素控释剂的抑瘤作用

目的：研究植入式丝裂霉素（MMC)控释剂对人肝癌裸鼠移植瘤的抑瘤作用。方法：将0.04、0.08、0.16mg3种不同剂量的丝裂霉素控释剂植入荷人肝癌裸小鼠皮下移植瘤内，并与MMC瘤内注射、MMC腹腔注射及对照组相比较，观察其抑瘤作用。结果：0.16mg瘤内植入组抑瘤率明显高于对照组（P=0.001)及0.04mg瘤内植入组（P=0.003)。0.16mg瘤内植入组抑瘤率也明显高于0.16mg腹腔注射组（P=0.003）.结论：植入式丝裂霉素控释剂是一种有效治疗原发性肝癌的药物新剂型，丝裂霉素控释剂瘤内植入可能成为临床治疗中晚期肝癌的新方法。     

载5-氟尿嘧啶聚乳酸纳米微粒瘤内注射治疗胃癌

目的观察生物可降解5-氟尿嘧啶聚乳酸纳米微粒（5-Fu-NPs）注射缓释剂用于肿瘤内局部给药的抗肿瘤活性。方法36只（SCID）小鼠随机分为6组，分别瘤内注射生理盐水的对照组、瘤内注射5．Fu．NPs（包括5-Fu20mg／kg体重和5-Fu30mg／kg体重）、无载药NPs、5-Fu注射液及腹腔注射5-Fu注射液，每3d瘤内给药1次共3次。观察荷瘤鼠肿瘤生长、荷瘤鼠给药前、后血象及给药后肿瘤组织凋亡指数。结果瘤内注射5-Fu-NPs缓释剂组小鼠肿瘤生长缓慢，瘤体明显小于5-Fu（含5-Fu20mg／kg体重）腹腔注射给药组，相应的抑瘤率分别为2．93％、22．87％、27．57％、41．64％和50．43％，其中以瘤内注射5-Fu-NPs对小鼠胃癌有较高抑瘤率，呈现良好的量效关系，且对骨髓的副作用为最小。结论瘤内应用5-Fu-NPs缓释剂的抗肿瘤效果优于局部和全身单纯5-Fu给药。     

靶向端粒酶催化亚单位基因hEST2反义寡核苷酸对人肝癌细胞生长的抑制作用

目的观察靶向端粒酶催化亚单位基因hEST2反义寡核苷酸对人肝癌细胞生长的抑制作用。方法从Genebank中钓取人端粒酶催化亚单位基因hEST2的mRNA序列，通过计算机模建二级结构辅助设计并合成硫化修饰反义寡核苷酸（癌泰得）。采用人肝癌裸小鼠原位移植模型（HCM—Y89）。实验分为生理盐水组，5-Fu10mg／kg组，癌泰得50mg／kg组、75mg／kg组，癌泰得75mg／kg联合5-Fu10mg／kg组、50mg／kg联合5-Fu10mg／kg组。尾静脉给药，每天1次，连续20d。观察移植瘤质量和抑瘤率、移植瘤体积、AFP浓度和移植瘤组织学。结果（1）5-Fu10mg／kg组的抑瘤率为27．85％，其他各治疗组的抑瘤率均在42．14％～74．29％之间；（2）各治疗组瘤质量、瘤体积和AFP浓度均低于生理盐水组且差异有统计学意义；（3）瘤体积和AFP浓度之间呈直线关系，为显著正相关（r=0．9977）；（4）癌泰得和5-FU治疗人肝细胞癌后，肝癌细胞出现不同程度的凋亡、坏死，同时伴有纤维组织增生。结论癌泰得对肝癌细胞生长具有抑制作用，疗效优于5-FU；与5-FU合用具有协同抗肿瘤效应。     

粉防己碱联合阿霉素对人膀胱癌BIU-87／ADM细胞裸鼠移植瘤抑瘤率影响的研究

目的观察粉防己碱（tetrandrine,Tet）联合阿霉素（adriamycin,ADM）对人膀胱癌BIU87／ADM细胞裸鼠移植瘤抑制率的影响。方法30只裸鼠腋部皮下接种BIU87／ADM移植瘤细胞,第22天扪及一小结节,随机分为对照组（生理盐水;6只）、ADM组（1．0mg／kgADM;6只）、Tet低剂量联合ADM组（1．0μg／mlTet＋1．0mg／kgADM;6只）、Tet中剂量联合ADM组（3．0ptg／m{Tet＋1．0mg／kgADM;6只）和Tet高剂量联合ADM组（5．0~g／mlTet＋1．0mg／kgADM;6只）,每4天于肿瘤局部注射生理盐水、ADM以及不同剂量的Tet＋1．0mg／kgADM,每4天测量肿瘤大小,并绘制肿瘤生长曲线;药物处理结束后取瘤并称取重量,依据公式计算抑瘤率。结果Tet各剂量联合ADM组肿瘤的体积、瘤重与对照组比较,差异有统计学意义（P％0．05）;Tet中、高剂量联合ADM组肿瘤体积、瘤重与ADM组比较,差异有统计学意义（P〈O．05）。结论Tet联合ADM能够明显增加ADM对膀胱癌细胞B1U一87／ADM移植瘤杀伤的敏感性,Tet剂量越高,抑制作用越明显。     

胰腺癌——胰腺癌的辅助化疗

胰腺癌的发病率近年来在世界范围内有逐年增高的趋势，虽然手术是治疗胰腺癌的根本手段，但目前胰腺癌手术切除率仅为10％～15％，因此围手术期化疗、放疗等综合治疗尤为重要。目前使用的化疗药物中5-氟脲嘧啶(5-Fu)和丝裂霉素(MMC)的抗胰腺癌作用较为肯定，广为临床应用。目前各化疗方案仍主要以5一Fu为基础，最常用的方案有：5-Fu 阿霉素(ADM) MMC；5-Fu 顺铂(DDP)；5-Fu 健择(GEM)等。     

人胆管细胞癌荷瘤裸鼠模型的建立

目前,外科手术、化疗和放疗对胆管癌的疗效均欠佳〔1〕。经确诊后胆管癌病人的总体生存期仅为6个月至5年不等〔2〕。基于为胆管癌研究提供一个肿瘤的体内实验系统目的,我们建立了荷人胆管癌裸鼠模型。方法:人胆管癌细胞系ＱＢＣ939(第三军医大学西南医院肝胆外科中心建株)在含10%ＦＢＳ的ＲＰＭＩ1640培养液中培养(37℃,5%ＣＯ2)。待细胞长至对数生长期,消化、收集培养中的细胞5×107,总体积为1.0ｍｌ,取0.1ｍｌ注入裸小鼠皮下〔3〕(10只)。每周测量并记录肿瘤的长径(ａ)和高度(ｂ)及裸小鼠的生存期。肿瘤生长曲线测绘方法:接种完成后,逐日…     

人肝门部胆管癌转移动物模型的建立及生物学特性研究

目的利用人肝门部胆管癌细胞系（FRH-0201）接种裸鼠脾脏，建立肝、肺转移模型。方法将FRH-0201细胞系（120代）接种于7只Balb／c裸小鼠脾脏。出现转移时，将转移瘤行组织病理学及超微结构观察。将转移的肿瘤行细胞培养，再次接种裸鼠脾脏，观察转移成瘤情况。结果脾脏局部成瘤率为100％（7／7），转移瘤发生率14．3％（1／7）。转移瘤细胞再次接种于裸小鼠脾脏，转移发生率100％。转移瘤电镜显示典型恶性细胞特征。转移瘤细胞染色体众数19条，主流范围18～44条。结论该实验所建立的肝门部胆管癌转移瘤，符合恶性肿瘤的特点，与人肝门部胆管癌生物学特性一致。     

联合TNP-470和MMC对小鼠肝癌术后复发和转移防治的实验研究

目的　研究血管形成抑制剂 TNP- 4 70联合 MMC对小鼠原位种植性肝癌术后复发和转移的防治作用。方法　原位肝癌模型小鼠切除肿瘤后建成肝癌切除术后小鼠模型 6 0只 ,随机分为四组 ,1对照组 :隔日皮下注射 3%酒精溶剂 ;2MMC组 :每周一次腹腔注射 MMC(2 m g/ Kg) ;3TNP- 4 70组 :隔日皮下注射 TNP- 4 70 (30 mg/ kg) ;4 TNP- 4 70 +MMC组 ;隔日皮下注射 TNP- 4 70 (30 m g/ kg) ,每周一次腹腔注射 MMC(2 mg/ kg) ,用药至小鼠死亡。检测小鼠存活时间、各组复发率、复发瘤体积、处理前后腹围。　结果　 1TNP- 4 70组及联合用药组较 MMC组和对照组生厚时间明显延长 (P<0 .0 5 ) ;2联合用药组较 MMC组复发率明显减少 ,复发瘤体积亦减少 (P<0 .0 5 ) ;3联合用药组较单药组小鼠腹围明显减少 (P<0 .0 5 )。结论　联合 TNP- 4 70及 MMC能明显提高单药对小鼠肝癌切除术后复发和转移的效果。     

不同浓度化疗药物对人肝癌细胞BEL-7404及BEL-7404/ADM端粒长度的影响

目的观察几种化疗药物对人肝癌BEL-7404、BEI，-7404／ADM细胞端粒长度的影响。方法采用SouthernBlotting及凝胶电泳法测定不同化疗药对人肝癌BEI，-7404、BEL-7404／ADM细胞端粒限制片断长度（TRF）的变化。结果亲本肝癌细胞中的平均端粒长度较肝癌耐药细胞端粒长度长（P〈0．05）。端粒长度随化疗药物浓度的增加而逐渐缩短：A、B组中DDP，MMC，ADM对BEL-7404、BEL-7404／ADM细胞均表现出明显的抑制性，组间比较表现为显著差异性（P〈0．01）；VCR对两种细胞的端粒长度均不具抑制性。C组DDP，ADM，MMC，VCR中的平均端粒长度皆与对照组相比有显著性差异（P〈0．05）。结论上述药物对端粒的抑制作用呈浓度效应关系，提示药物对端粒长度的影响不仅与药物的作用浓度有关，而且与其肿瘤细胞的耐药性有关。     

Effect of various anti-cancer drugs on human renal cell carcinoma serially transplanted into nude mice

Using two xenografts of human renal cell carcinomas serially transplanted in nude mice (AM-RC-1 and AM-RC-6), both of which maintained the basic histologic features of the original tumor and showed a constant growth rate, the effects of various anticancer agents against 2 target tumors were evaluated. MitomycinC (MMC), adriamycin (ADM), cisplatinum diaminodichloride (CDDP), 5-fluorouracil (5FU), 5-fluro-2'-deoxy-beta-uridine (FUDR) and human lymphoblastoid interferon (HLBI) against AM-RC-1, and MMC, ADM, CDDP, vinblastin (VBL) and etoposide (VP-16) against AM-RC-6. Drugs other than HLBI were administered 3 times in total every three to five days by intraperitoneal injection according to Battelle Columbus Laboratories Protocol and HLBI was injected daily for 10 days intraperitoneally. Anti-cancer effects were evaluated based on tumor growth curve and changes of histologic findings. In terms of tumor growth only MMC (in a dose of 3 mg/kg) revealed a statistically significant inhibitory effect against both AM-RC-1 and AM-RC-6 (respectively P less than 0.001 and P less than 0.05). Concerning AM-RC-1, a significant difference (P less than 0.01) was recognized in the ADM group (5 mg/kg) at the time of the second administration, but evaluation could not ultimately be done owing to appearance of acute toxity after the last dose. The most remarkable histologic changes by light microscopy were recognized in the MMC group (in a dose of 3 mg/kg) against AM-RC-1. They were degenerative findings such as intracellular and nuclear vacuolation, karyorrhexis, karyolysis, karyopyknosis and marginal hyperchromatosis, which corresponded to grade IIa of the classification of the National Cancer Center. The other drugs administered to AM-RC-1 exhibited only grade O to grade I changes. On the other hand, in AM-RC-6, histologic changes were mild (less than grade II) for all the drugs. Electron microscopic features were as follows. AM-RC-1: Marked increase of vacuole of organella was observed and lumens were filled with a large quantity of debris in MMC group (3 mg/kg). In the ADM group (5 mg/kg) there was debris in lumens, although almost no changes of organella were seen. CDDP groups (both 5.6 mg/kg and 2.8 mg/kg) showed autophagic vacuole in the cytoplasm and increased collagen fibers in the stroma but little changes of organella. AM-RC-6: Mild intracellular vacuolation was recognized in the MMC group (3 mg/kg). Watery degeneration and microfibrils were found in the cytoplasm in both ADM (5 mg/kg) and CDDP (5.6 mg/kg, 2.8 mg/kg) groups.     

人胆管癌裸鼠移植瘤模型的建立

目的：建立人胆管癌裸鼠移植瘤1号和2号模型。方法：将人胆管癌组织接种于裸鼠皮下和肝脏，逐代观察移植瘤的生长情况，绘制其生长曲线，进行形态学和生物学特性鉴定。结果：建立了人胆管高分化粘液腺癌裸鼠移植瘤1号和中分化乳头状腺癌裸鼠移植瘤2号模型。皮下移植瘤生长率为40％；1、2号模型移植成功率分别为97．7％和100％，潜伏期分别为26d和217d。移植瘤在形态和生物学上仍保持人胆管癌的特点。结论：裸鼠移植瘤1、2号模型是一种接近人体的胆管癌模型，可为胆管癌研究提供实验平台。     

Antitumor effect of alpha-difluoromethylornithine (DFMO) changes in ornithine decarboxylase (ODC) activity and polyamine (PA) levels in human tumor transplanted into nude mice

Three human carcinoma xenografts serially transplanted into nude mice were used for the study of antitumor effect of DFMO. One breast carcinoma (MX-1) and two colon carcinomas (Exp-42, Co-3) were inoculated into the subcutaneous tissue of BALB/c nude mice. When the tumor weights reached 100 -300mg, 0.5%, 1% and 2% DFMO was administrated ad libitum in tap water for 21 days, MMC was administrated ip q7d x 3(DAY 0, 7,14) at 0.5mg/kg or 2.0mg/kg. Combination of 1% DFMO and MMC 1mg/kg x 3 using a similar schedule was also made. After 21 days, the tumors were weighed and assays of ODC activity and analysis of PA in the tumors were done. The antitumor effects (the lowest value of TRW/CRW) of 2% DFMO against MX-1, Exp-42 and Co-3 were 4.83%, 35.8% and 73.4% respectively. Synergic effects of MMC were observed in all three tumors. With 2% DFMO, ODC and PUT levels were decreased to 16.4%, 2.89% of control in MX-1, 14.8%, 6.62% in Exp-42, 4.18%, 11.2% in Co-3 respectively. Of MX-1 and Exp-42, the dose of DFMO administrated, the antitumor effect and the PUT levels were correlated (p less than 0.05). DFMO is one of the potent chemotherapeutic agents and may be useful in combination chemotherapy.     

反应停对人肝细胞癌生长侵袭的作用

目的 观察反应停对人肝细胞癌（HCC）血管生成和肿瘤生长侵袭的干预作用。方法 建立高转移潜能人肝癌裸鼠肝原位移植模型，随机分成4组。各组模型自建立次日起分别经腹腔注射0．5％羧甲基纤维素钠（CMC）、反应停（200mg／kg体重）、紫杉醇（13mg／kg体重）、反应停（200mg／kg体重）＋紫杉醇（13mg／d）。给药第30天处死裸小鼠，观察肿瘤生长、转移情况，分别用免疫组织化学和半定量逆转录．聚合酶链反应（RT—PCR）的方法检测癌组织CD34和血管内皮生长因子（VEGF）mRNA的表达并记录微血管密度（MVD）。结果 反应停组肿瘤重量、体积均与空白对照组差异无统计学意义（P〉0．05）。各药物处理组肺转移灶计数、MVD和VEGF均低于对照组，以联合用药组最为显著。结论 反应停对HCC生长无明显抑制作用，但能抑制肿瘤血管生成并降低肺转移。     

Experimental chemo- and chemoendocrine therapy of human breast carcinomas serially transplanted into nude mice

Four human breast carcinoma strains serially transplanted into nude mice were used for the experimental chemotherapy and combination chemoendocrine therapy. Whereas three of these strains (MCF-7, Br-10, TM-61) possessed cytosol estrogen receptor (ERc) and were dependent on estradiol for the tumor growth, the other strain (MX-1) without ERc was hormone independent. For the chemotherapy, mitomycin C (MMC), adriamycin (ADM), cyclophosphamide (CPM) and 5-fluorouracil (5-FU) were administered 3 times every 4 days. To know the stability of ERc after chemotherapy, binding sites of ERc were measured 4 days after MMC administration at doses of 1, 2 and 4.5 mg/kg. For the chemoendocrine therapy, 1 or 2 mg/kg of MMC was administered once followed by treatment by tamoxifen (TAM). The effect of treatment was evaluated by T/C ratio of the tumor weight. MMC showed the most excellent antitumor effect and CPM and ADM showed a moderate effect. As ERc was found to be stable by MMC treatment, TAM was used after MMC, and this combination of MMC and TAM revealed an additive effect against ERc positive strains and no combination effect was observed in MX-1 without ERc. The dose response curves of 4 strains to MMC alone against 4 strains were made and the effect of combination chemoendocrine therapy was converted to the effect of MMC alone, showing the dose of MMC could be significantly reduced. Binding sites of ERc which were measured 4 days after MMC administration (1, 2 and 4.5 mg/kg) was found to be stable, suggesting TAM treatment after MMC might be reasonable. From these results, chemoendocrine therapy of MMC followed by TAM was considered to be beneficial modality for clinical treatment of the cytotoxic agent and increasing the antitumor effect.     

恶性骨肿瘤化疗药物敏感性研究

目的　分析恶性骨肿瘤化疗药物敏感性和多药耐药性 ,为制定敏感的个体化化疗方案提供依据。　方法　取恶性骨肿瘤新鲜标本 3 2例 (骨肉瘤 2 0例 ,其它恶性肿瘤 12例 ) ,运用流式细胞术检测化疗药物作用后的瘤细胞凋亡情况及其P170蛋白表达 ,分析其化疗敏感性和耐药性。结果　不同化疗药物作用后的骨肉瘤细胞凋亡百分比分别为 :甲氨喋呤 ( 3 0 5 0± 10 2 2 ) % ,阿霉素( 2 6 2 8± 9 3 5 ) % ,丝裂霉素 ( 2 3 11± 7 3 8) % ,足叶乙甙 ( 18 17± 6 14 ) % ,长春新碱 ( 4 4 4± 2 5 5 ) % ,环磷酰胺 ( 1 2 2± 0 5 9) %。P170蛋白表达较高者化疗敏感性均较低。　结论　流式细胞术分析化疗药物作用后的恶性骨肿瘤细胞凋亡及其P170蛋白表达 ,对预测肿瘤的化疗敏感性和耐药性有一定意义。     

Combination chemotherapy of human renal cell carcinoma in athymic nude mice with human lymphoblastoid interferon (HLBI) and UFT, 5-Fu

The effectiveness of interferon alpha (HLBI) for nude mouse transplantable human renal cell carcinoma 72nd general meeting, in combination with UFT and 5-Fu, was examined using, 1 x 10(7) IU/kg, 2 x 10(7) IU/kg HLBI; 25 mg/kg 5-Fu; and 10 mg/kg, 20 mg/kg UFT, administered for 10 consecutive days. The ratio of relative mean tumor weight of treated group to control group was under 42% for the combination of 25 mg/kg (I.P.) 5-Fu, 20 mg/kg UFT, and HLBI and the effect was particularly clear for the combination with 2 x 10(7) IU/kg which indicated a grade IIA histologic classification. In comparison with the control groups only UFT (20 mg/kg) and HLBI (2 x 10(7) IU/kg) showed significant inhibition when administered alone. Although none of the drugs had an inhibitory effect when administered alone, in combined use they showed a strong antitumor effect which was more than synergistic. Orally administered 5-Fu showed a statistically significant difference only in the combination with 2 x 10(7) IU/kg HLBI. Furthermore, the concentration of 5-Fu in the tumor tissue was not affected by the route of administration or drug combination, whereas that in the serum was below the limit of detection in the intraperitoneally administered cases, 0.0096 +/- 0.0079 microgram/ml, lower than the value for orally administered cases. The 5-Fu concentration was 0.026 +/- 0.012 microgram/ml for orally administered UFT which was significantly higher than the value obtained for orally administered 5-Fu. Thus, combination therapy of HLBI and UFT for renal cell carcinoma is expected to be clinically useful.     

放射性碘标记表皮生长因子核素靶向治疗乳腺癌的实验研究

目的　观察放射性核素碘 (13 1I)偶联表皮生长因子 (EGF)对人乳腺癌裸鼠移植瘤的作用 ,探讨其靶向治疗乳腺癌的有效性和可行性。方法　氯胺 T法碘标EGF和人血清白蛋白 ;建立表达表皮生长因子受体 (EGFR)的人乳腺癌荷瘤裸鼠模型 ,36只裸鼠模型分为 6组 ,分别为阴性对照组、阳性对照组、13 1I EGF静脉组、13 1I 白蛋白组、13 1I组和13 1I EGF瘤内注射组 ,每组 6只。观察肿瘤生长增殖情况及放射性核素碘标EGF对正常组织脏器的放射毒副作用。结果　自第 1次给药后第 7天至第2 6天各时间段 ,13 1I EGF静脉和瘤内注射组肿瘤体积与阴性对照组、13 1I组及13 1I 白蛋白组肿瘤体积差异有统计学意义 (P <0 0 1) ;13 1I EGF静脉和瘤内注射组抑瘤率分别为 82 0 %和 80 7% ,与13 1I组和13 1I 白蛋白组比较 (抑瘤率分别为 7 4 9%、6 91% ) ,差异有统计学意义 (P <0 0 1) ;光学显微镜和透射电镜下见13 1I EGF静脉和瘤内注射组肿瘤细胞发生了一系列不可逆损害变化 ;未发现肝、肾和骨髓非特异性放射损伤。结论　经EGF转载的13 1I对人乳腺癌裸鼠移植瘤有明显抑制肿瘤细胞增殖生长的作用 ,无明显毒副作用。     

人胃癌细胞原位移植裸鼠原发灶与肝转移灶体外化疗药敏性差异

目的：比较人胃癌原位移植裸鼠肝转移模型原发灶、肝转移灶肿瘤细胞对化疗药物敏感性。 方法：将裸鼠皮下传代的SGC-7901细胞株实体瘤组织块移植于裸鼠胃壁,建立人胃癌裸鼠原位移植模型,待其发生肝转移后取胃原发灶、肝转移灶肿瘤细胞,SRB法检测肿瘤细胞对氟尿嘧啶（5-FU）,顺铂（CDDP）,奥沙利铂（L-OHP）,表阿霉素（eADM）,丝裂霉素（MMC）,长春新碱（VCR）,氨甲喋呤（MTX）7种化疗药物的体外敏感性。 结果：成功建立裸鼠原位移植胃癌转移模型,肿瘤原位移植成瘤率100%,肝转移率75%;7种药物中L-OHP,VCR对原发灶肿瘤细胞的抑制率高于肝转移灶,而eADM,MMC对肝转移灶肿瘤细胞的抑制率高于原发灶（均P<0.05）;5-FU,L-OHP,MTX对原发灶与肝转移灶的抑制率具正相关性（r=0.5203;0.4424;0.3851,均P<0.05）。 结论：胃癌原位移植动物的原发灶和肝转移灶细胞的对化疗药物药敏性存在差异,以原发灶药敏检测结果指导针对肝转移灶的治疗可能是不准确的。